Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alectinib + osimertinib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two targeted therapies used primarily for the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. Alectinib is an ALK tyrosine kinase inhibitor that targets ALK rearrangements, while osimertinib is a third-generation EGFR tyrosine kinase inhibitor that targets EGFR mutations, particularly those with T790M resistance mutations. This combination has shown effectiveness in treating patients with concurrent EGFR and ALK alterations, especially in cases of resistance to single-agent therapy and in managing brain metastases.
- Other names
- osimertinib plus alectinibosimertinib and alectinib
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on alectinib + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alectinib + osimertinib.